Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa Bersanelli

Showing results (1-10 of 151) with videos related to

Pageof 16
Sort By:
Immunotherapy|March 28, 2020
Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitorsMelissa Bersanelli
The Lancet. Oncology|September 13, 2020
Tumour mutational burden as a driver for treatment choice in resistant tumours (and beyond)Melissa Bersanelli
Immunotherapy|September 22, 2020
COVID-19 and the newly rediscovered multidisciplinarityMelissa Bersanelli
Recenti Progressi in Medicina|May 6, 2024
[Advanced melanoma with low-burden and low-risk disease: a clinical case.]Melissa Bersanelli
Therapeutic Advances in Medical Oncology|October 5, 2017
Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potentialMelissa Bersanelli, Sebastiano Buti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2017
Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?Sebastiano Buti, Melissa Bersanelli
Future Oncology (London, England)|May 12, 2016
The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trialsSebastiano Buti, Melissa Bersanelli
World Journal of Clinical Oncology|March 2, 2017
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axisMelissa Bersanelli, Sebastiano Buti
The New England Journal of Medicine|December 16, 2020
Avelumab Maintenance for Urothelial CarcinomaSebastiano Buti, Melissa Bersanelli
Acta Bio-Medica : Atenei Parmensis|May 11, 2016
Upfront Chemohormonal Therapy for Prostate Cancer: Neutropenia and G-CSF UseSebastiano Buti, Melissa Bersanelli
Pageof 16

Showing results (1-10 of 151) with videos related to

Sort By:
Pageof 16
Immunotherapy|March 28, 2020
Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitorsMelissa Bersanelli
The Lancet. Oncology|September 13, 2020
Tumour mutational burden as a driver for treatment choice in resistant tumours (and beyond)Melissa Bersanelli
Immunotherapy|September 22, 2020
COVID-19 and the newly rediscovered multidisciplinarityMelissa Bersanelli
Recenti Progressi in Medicina|May 6, 2024
[Advanced melanoma with low-burden and low-risk disease: a clinical case.]Melissa Bersanelli
Therapeutic Advances in Medical Oncology|October 5, 2017
Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potentialMelissa Bersanelli, Sebastiano Buti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2017
Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?Sebastiano Buti, Melissa Bersanelli
Future Oncology (London, England)|May 12, 2016
The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trialsSebastiano Buti, Melissa Bersanelli
World Journal of Clinical Oncology|March 2, 2017
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axisMelissa Bersanelli, Sebastiano Buti
The New England Journal of Medicine|December 16, 2020
Avelumab Maintenance for Urothelial CarcinomaSebastiano Buti, Melissa Bersanelli
Acta Bio-Medica : Atenei Parmensis|May 11, 2016
Upfront Chemohormonal Therapy for Prostate Cancer: Neutropenia and G-CSF UseSebastiano Buti, Melissa Bersanelli
Pageof 16